for the ProtecT study group. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial (vol 15, pg 1109, 2014)

被引：0
|
作者：
Lane, J. A.
Donovan, J. L.
Davis, M.
机构：
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E475 / E475
页数：1
相关论文
共 26 条
  • [21] Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study (vol 15, pg 620, 2014)
    Corrie, P. G.
    Marshall, A.
    Dunn, J. A.
    LANCET ONCOLOGY, 2014, 15 (09): : E365 - E365
  • [22] Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. (vol 17, pg 747, 2016)
    Carrie, C.
    Hasbini, A.
    de Laroche, G.
    LANCET ONCOLOGY, 2016, 17 (06): : E223 - E223
  • [23] A Phase II Prospective Multi-Institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903 (vol 15, pg 158, 2008)
    Posner, Mitchell C.
    Niedzwiecki, Donna
    Venook, Alan P.
    Hollis, Donna R.
    Kindler, Hedy L.
    Martin, Edward W.
    Schilsky, Richard L.
    Goldberg, Richard M.
    Mayer, Robert J.
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (08) : 2381 - 2381
  • [24] Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE- B): 2-year toxicity results from an open- label, randomised, phase 3, non-inferiority trial. (vol 23, pg 1308, 2022)
    Li, Z.
    Liu, P.
    Wang, Z.
    LANCET ONCOLOGY, 2023, 24 (05): : E192 - E192
  • [25] Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study (vol 208, pg 1226, 2022)
    De, Brian
    Pasalic, Dario
    Barocas, Daniel A.
    Wallis, Christopher J. D.
    Huang, Li-Ching
    Zhao, Zhiguo
    Koyama, Tatsuki
    Tang, Chad
    Goodman, Michael
    Hamilton, Ann S.
    Wu, Xiao-Cheng
    Paddock, Lisa E.
    Stroup, Antoinette
    Cooperberg, Matthew R.
    Hashibe, Mia
    O'Neil, Brock B.
    Kaplan, Sherrie H.
    Greenfield, Sheldon
    Penson, David F.
    Hoffman, Karen E.
    JOURNAL OF UROLOGY, 2023, 209 (02): : 450 - 450
  • [26] Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial (vol 165, pg 573, 2017)
    Nitz, Ulrike
    Gluz, Oleg
    Christgen, Matthias
    Kates, Ronald E.
    Clemens, Michael
    Malter, Wolfram
    Nuding, Benno
    Aktas, Bahriye
    Kuemmel, Sherko
    Reimer, Toralf
    Stefek, Andrea
    Lorenz-Salehi, Fatemeh
    Krabisch, Petra
    Just, Marianne
    Augustin, Doris
    Liedtke, Cornelia
    Chao, Calvin
    Shak, Steven
    Wuerstlein, Rachel
    Kreipe, Hans H.
    Harbeck, Nadia
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) : 265 - 266
123